RTP Mobile Logo
Select Publications

Roy S Herbst, MD, PhD

Forde PM et al. Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment (tx) for resectable (IB-IIIA) non-small cell lung cancer (NSCLC) in the phase 3 CheckMate 816 trial. AACR 2021;Abstract CT003.

Leonetti A et al. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer 2019;121(9):725-37. Abstract

Majem M et al. Patient-reported outcomes from ADAURA: Osimertinib as adjuvant therapy in patients with resected EGFR mutated (EGFRm) NSCLC. WCLC 2020;Abstract OA06.03.

Ramalingam SS et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med 2020;382(1):41-50. Abstract

Spicer J et al. Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC). ASCO 2021;Abstract 8503.

Wakelee HA et al. IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC). ASCO 2021;Abstract 8500.

Wu Y-L et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med 2020;383(18):1711-23. Abstract

Sara M Tolaney, MD, MPH

Domchek SM et al. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): An open-label, multicentre, phase 1/2, basket study. Lancet Oncol 2020;21(9):1155-64. Abstract

Harbeck N et al. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: Updated efficacy and Ki-67 analysis from the monarchE study. Ann Oncol 2021;32(12):1571-81. Abstract

Loibl S et al. Durvalumab improves long-term outcome in TNBC: Results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC). ASCO 2021;Abstract 506.

O’Shaughnessy J et al. Adjuvant abemaciclib combined with endocrine therapy (ET): Updated results from monarchE. ESMO 2021;Abstract VP8-2021.

Royce M et al. FDA approval summary: Abemaciclib with endocrine therapy for high-risk early breast cancer. J Clin Oncol 2022;[Online ahead of print]. Abstract

Schmid P et al. KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC. ESMO Virtual Plenary 2021;Abstract VP7-2021.

Tutt ANJ et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med 2021;384(25):2394-405. Abstract

Jeffrey S Weber, MD, PhD

Amaria RN et al. Neoadjuvant and adjuvant nivolumab (nivo) with anti-LAG3 antibody relatlimab (rela) for patients (pts) with resectable clinical stage III melanoma. ASCO 2021;Abstract 9502.

Eggermont AM et al. Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase 3 trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma. ASCO 2021;Abstract 9500.

Long GV et al. Adjuvant therapy with nivolumab (NIVO) combined with ipilimumab (IPI) vs NIVO alone in patients (pts) with resected stage IIIB-D/IV melanoma (CheckMate 915). AACR 2021;Abstract CT004.

Luke JJ et al. Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the KEYNOTE-716 double-blind phase III trial. ESMO 2021;Abstract LBA3.

Rozeman EA et al. Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma. Nat Med 2021;27(2):256-63. Abstract

Weber J et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med 2017;377(19):1824-35. Abstract